AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Biomedicine and Engineering Article
PDF (435.6 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Article | Open Access

In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines

Mukta Bagul1,2, Srikanth Kakumanu1,2, Thomas Wilson1,2, Robert Nicolosi1,2( )
Center for Health and Disease Research – Division of NanoMedicine, Department of Clinical Laboratory and Nutritional Sciences
The Biomedical Engineering/Biotechnology Ph.D. Program, University of Massachusetts Lowell, Lowell, MA 01854
Show Author Information

Abstract

Paclitaxel is routinely used in cancer chemotherapy to treat patients with ovarian, breast, lung, head and neck cancers. However, because of its low aqueous solubility, it’s been administered as a Cremophor EL and ethanol solution, which is associated with increased toxicity and high therapeutic dose requirements. The goal of the present study was to formulate paclitaxel into a self assembling nanoemulsion (SANE) and demonstrate the effects of paclitaxel SANE formulation on the inhibition of cell proliferation in breast (80 %), colon (60 %), and pancreatic cell lines (60 %) compared to blank nanoemulsion. In addition, nanoemulsions of paclitaxel with a mean particle size of 20 nm dramatically reduced zeta potential and showed up to 12 fold greater apoptosis in the PL-45 pancreatic cancer cell line compared to a blank nanoemulsion. In conclusion we have developed a SANE formulation of paclitaxel having a particle size of 20 nm which significantly inhibited cell proliferation, dramatically reduced zeta potential and increased apoptosis by 12-fold when compared to a blank and nanoemulsion, thus indicating the therapeutic potential for SANE as an anti-cancer drug delivery system.

Keywords

PaclitaxelCell proliferationPancreaticSelf assembling nanoemulsionsBreast and colon cancer cell lines

References

1

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ:Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2):106-130. doi: 10.3322/canjclin.56.2.106
Crossref Google Scholar
2

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ:Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. doi: 10.3322/CA.2007.0010
Crossref Google Scholar
3

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ:Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43- 66.doi: 10.3322/canjclin.57.1.43
Crossref Google Scholar
4

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ:Can-cer statistics, 2009. CA Cancer J Clin 2009, 59(4):225- 249.doi: 10.3322/caac.20006
Crossref Google Scholar
5

Newcomb PA, Carbone PP:Cancer treatment and age:patient perspectives. J Natl Cancer Inst 1993, 85(19):1580-1584. doi: 10.1093/jnci/85.19.1580
Crossref Google Scholar
6

Carter SK:Integration of chemotherapy into combined modality treatment of solid tumors Ⅶ. Adenocarcinoma of the breast. Cancer Treat Rev 1976, 3(3):141- 174.doi: 10.1016/S0305-7372(76)80020-5
Crossref Google Scholar
7

Carter SK, Comis RL:The integration of chemotherapy into a combined modality approach for cancer treatment. Ⅵ. Pancreatic adenocarcinoma. Cancer Treat Rev 1975, 2(3):193-214. doi: 10.1016/S0305-7372(75)80003-X
Crossref Google Scholar
8

Wang MD, Shin DM, Simons JW, Nie S:Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther 2007, 7(6):833-837. doi: 10.1586/14737140.7.6.833
Crossref Google Scholar
9

Zhang R, Wang X, Wu C, Song M, Li J, Lv G, Zhou J, Chen C, Dai Y, Gao F, Fu D, Li X, Guan Z, Chen B:Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology 2006, 17(14):3622-3626. doi: 10.1088/0957-4484/17/14/043
Crossref Google Scholar
10

Yang YY, Wang Y, Powell R, Chan P:Polymeric coreshell nanoparticles for therapeutics. Clin Exp Pharmacol Physiol 2006, 33(5-6):557-562. doi: 10.1111/j.1440-1681.2006.04408.x
Crossref Google Scholar
11

Wang X, Wang Y, Chen ZG, Shin DM:Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009, 41(1):1-11. doi: 10.4143/crt.2009.41.1.1
Crossref Google Scholar
12

Gotaskie GE, Andreassi BF:Paclitaxel:a new antimitotic chemotherapeutic agent. Cancer Pract 1994, 2(1):27-33.
Google Scholar
13

Hortobagyi GN, Holmes FA:Single-agent paclitaxel for the treatment of breast cancer:an overview. Semin Oncol 1996, 23(1):4-9.
Google Scholar
14

Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN:Phase Ⅱ study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 2000, 89(11):2195-2201. doi: 10.1002/1097-0142(20001201)89:11<2195::AID-CNCR7>3.0.CO;2-W
Crossref Google Scholar
15

Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN:Phase Ⅱ trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797-1805. doi: 10.1093/jnci/83.24.1797-a
Crossref Google Scholar
16

Foa R, Norton L, Seidman AD:Taxol (paclitaxel):a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994, 24(1):6-14. doi: 10.1007/BF02592403
Crossref Google Scholar
17

Guppy AE, Nathan PD, Rustin GJ:Epithelial ovarian cancer:a review of current management. Clin Oncol (R Coll Radiol) 2005, 17(6):399-411. doi: 10.1016/j.clon.2005.05.009
Crossref Google Scholar
18

Yeung TK, Germond C, Chen X, Wang Z:The mode of action of taxol:apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 1999, 263(2):398-404. doi: 10.1006/bbrc.1999.1375
Crossref Google Scholar
19

Singla AK, Garg A, Aggarwal D:Paclitaxel and its formulations. Int J Pharm 2002, 235(1-2):179-192. doi: 10.1016/S0378-5173(01)00986-3
Crossref Google Scholar
20

Gelderblom H, Verweij J, Nooter K, Sparreboom A:Cremophor EL:the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37(13):1590-1598. doi: 10.1016/S0959-8049(01)00171-X
Crossref Google Scholar
21

Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC:Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20(4):1-15.
Google Scholar
22

Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V:Paclitaxel-loaded PEGylated PLGA-based nanoparticles:in vitro and in vivo evaluation. J Control Release 2009, 133(1):11-17. doi: 10.1016/j.jconrel.2008.09.086
Crossref Google Scholar
23

Miele E, Spinelli GP, Tomao F, Tomao S:Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99- 105.
Crossref Google Scholar
24

Sinha R, Kim GJ, Nie S, Shin DM:Nanotechnology in cancer therapeutics:bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5(8):1909-1917. doi: 10.1158/1535-7163.MCT-06-0141
Crossref Google Scholar
25

Kotyla T, Kuo F, Moolchandani V, Wilson T, Nicolosi R:Increased bioavailability of a transdermal application of a nano-sized emulsion preparation. Int J Pharm 2008, 347(1-2):144-148. doi: 10.1016/j.ijpharm.2007.06.045
Crossref Google Scholar
26

Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, Kim DD:Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv 2007, 14(5):301-308. doi: 10.1080/10717540601098799
Crossref Google Scholar
27

Nobs L, Buchegger F, Gurny R, Allemann E:Biodegradable nanoparticles for direct or two-step tumor immunotar-geting. Bioconjug Chem 2006, 17(1):139-145. doi: 10.1021/bc050137k
Crossref Google Scholar
28

Kuo F, Subramanian B, Kotyla T, Wilson TA, Yoganathan S, Nicolosi RJ:Nanoemulsions of an anti-oxidant synergy formulation containing gamma tocopherol have enhanced bioavailability and anti-inflammatory properties. Int J Pharm 2008, 363(1-2):206-213. doi: 10.1016/j.ijpharm.2008.07.022
Crossref Google Scholar
29

Subramanian B, Kuo F, Ada E, Kotyla T, Wilson T, Yoganathan S, Nicolosi R:Enhancement of anti-inflammatory property of aspirin in mice by a nano-emulsion preparation. Int Immunopharmacol 2008, 8(11):1533-1539. doi: 10.1016/j.intimp.2008.06.009
Crossref Google Scholar
30

Shea T, Ortiz D, Nicolosi R, Kumar R, Watterson A:Na-nosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta. J Alzheimer's Dis 2005, 7(4):297-301.
Crossref Google Scholar
31

Hancock A, Nakuci E, Nicolosi R, Shea T:An antitoxidant formulation that induces differentiation of neuroblastoma in culture. Neurosci Res Commun 2003, 33(1):73- 76.doi: 10.1002/nrc.10082
Crossref Google Scholar
32

Tagne JB, Kakumanu S, Nicolosi RJ:Nanoemulsion Preparations of the Anticancer Drug Dacarbazine Significantly Increase Its Efficacy in a Xenograft Mouse Melanoma Model. Mol Pharm 2008,.
Crossref Google Scholar
33

Tagne JB, Kakumanu S, Ortiz D, Shea T, Nicolosi RJ:A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol Pharm 2008, 5(2):280-286. doi: 10.1021/mp700091j
Crossref Google Scholar
34

Chono S, Tauchi Y, Morimoto K:Influence of Particle Size on the Distributions of Liposomes to Atherosclerotic Lesions in Mice. Drug Dev Ind Pharm 2006, 32(1):125- 135.doi: 10.1080/03639040500390645
Crossref Google Scholar
35

Gaumet M, Vargas A, Gurny R, Delie F:Nanoparticles for drug delivery:The need for precision in reporting particle size parameters. European Journal of Pharmaceutics and Biopharmaceutics 2008, 69(1):1-9. doi: 10.1016/j.ejpb.2007.08.001
Crossref Google Scholar
36

36. Lee M, Lim S, Kim C:Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007, 28(12):2137-2146. doi: 10.1016/j.biomaterials.2007.01.014
Crossref Google Scholar
37
Snedecor GW Cochran WG Ames IA Statistical methodsThe Iowa State University Press1980

Snedecor GW, Cochran WG, Ames IA.:Statistical methods. The Iowa State University Press; 1980.
38

Hait WN, Hambley TW:Targeted cancer therapeutics. Cancer Res 2009, 69(4):1263-7; discussion 1267. doi: 10.1158/0008-5472.CAN-08-3836
Crossref Google Scholar
39

Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA:Emerging nanopharmaceuticals. Nanomedicine 2008, 4(4):273-282.
Crossref Google Scholar
40

Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H:Introducing nanochemoprevention as a novel approach for cancer control:proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 2009, 69(5):1712-1716. doi: 10.1158/0008-5472.CAN-08-3978
Crossref Google Scholar
41

Brayton CF:Dimethyl sulfoxide (DMSO):a review. Cornell Vet 1986, 76(1):61-90.
Google Scholar
42

Cho K, Wang X, Nie S, Chen ZG, Shin DM:Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14(5):1310-1316. doi: 10.1158/1078-0432.CCR-07-1441
Crossref Google Scholar
43

Sykes E, Woodburn K, Decker D, Kessel D:Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 1994, 70(3):401-404.
Crossref Google Scholar
44

Nornoo AO, Osborne DW, Chow DS:Cremophor-free intravenous microemulsions for paclitaxel Ⅰ:formulation, cytotoxicity and hemolysis. Int J Pharm 2008, 349(1-2):108-116. doi: 10.1016/j.ijpharm.2007.07.042
Crossref Google Scholar
45

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A:Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002, 8(4):1237-1241.
Google Scholar
46

Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU:Use of Taxol (paclitaxel) in breast cancer. Oncology 1994, 51 Suppl 1:29-32. doi:10.1159/000227413
Crossref Google Scholar
Nano Biomedicine and Engineering
Volume 2 Issue 2,
June 2010
Pages 100-108
DOI: 10.5101/nbe.v2i2.p100-108
Cite this article:
Bagul M, Kakumanu S, Wilson T, et al. In vitro Evaluation of Antiproliferative Effects of Self-assembling Nanoemulsion of Paclitaxel on Various Cancer Cell Lines. Nano Biomedicine and Engineering, 2010, 2(2): 100-108. https://doi.org/10.5101/nbe.v2i2.p100-108

345

Views

9

Downloads

5

Crossref

14

Scopus

Altmetrics
Received: 16 May 2010
Accepted: 20 June 2010
Published: 26 June 2010
© 2010 M. Bagul et al.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Return